Abstract: Novel markers for breast cancer that are both sensitive and accurate. These markers are overexpressed in breast cancer specifically, as opposed to normal breast tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of breast cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between breast cancer and non-cancerous states.

Abstract: Novel markers for cardiac disease that are both sensitive and accurate. These markers are differentially and/or specifically expressed in cardiac tissue, as opposed to other types of tissues, optionally and preferably including muscle tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of cardiac disease, including pathology and/or damage, including acute and/or chronic damage. The markers of the present invention, alone or in combination, show a high degree of differential detection between cardiac disease states and non-cardiac disease states.

Abstract: A method of diagnosing predisposition to, or presence of ovarian cancer, breast cancer and/or lung cancer in a subject is provided. The method comprises determining a level of SIM2 in a lung tissue, breast tissue and/or ovarian tissue of the subject, the level being correlatable with predisposition to, or presence or absence of the ovarian cancer, breast cancer and/or lung cancer, thereby diagnosing predisposition to, or presence of ovarian cancer, breast cancer and/or lung cancer in the subject.

Abstract: Novel markers for lung cancer that are both sensitive and accurate. These markers are overexpressed in lung cancer specifically, as opposed to normal lung tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of lung cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between lung cancer and non-cancerous states.

Abstract: Novel markers for ovarian cancer that are both sensitive and accurate. These markers are overexpressed and/or differentially expressed in ovarian cancer specifically, as opposed to normal ovarian tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis, in ovarian cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between ovarian cancer and non-cancerous states.

Abstract: An isolated polynucleotide is provided. The isolated polynucleotide comprising a nucleic acid sequence encoding a UbcH10 polypeptide having at least a portion of an amino acid sequence at least 55% homologous to SEQ ID NO:7, as determined using the BlastP software of the National Center of Biotechnology Information (NCBI) using default parameters.

Abstract: Isolated polynucleotides encoding novel ErbB-2 polypeptides are provided. Also provided are methods and kits using same for diagnosing prognosing and treating ErbB-related cancer.

Abstract: A method of identifying putative naturally occurring antisense transcripts is provided. The method is effected by (a) computationally aligning a first database including sense-oriented polynucleotide sequences with a second database including expressed polynucleotide sequences; and (b) identifying expressed polynucleotide sequences from the second database being capable of forming a duplex with at least one sense-oriented polynucleotide sequence of the first database, thereby identifying putative naturally occurring antisense transcripts. Also provided are polynucleotides and polypeptide sequences identified by the above-described methodology.

Abstract: A method of identifying putative naturally occurring antisense transcripts is provided. The method is effected by (a) computationally aligning a first database including sense-oriented polynucleotide sequences with a second database including expressed polynucleotide sequences; and (b) identifying expressed polynucleotide sequences from the second database being capable of forming a duplex with at least one sense-oriented polynucleotide sequence of the first database, thereby identifying putative naturally occurring antisense transcripts.